Interim results for MRG-106
BOULDER, Colo.—miRagen Therapeutics Inc. has released interim results from its ongoing Phase 1 clinical trial of MRG-106 with the mycosis fungoides form of cutaneous T-cell lymphoma. Among the results, nine of 14 patients (64 percent) who were treated for more than a month saw a 50-percent or greater improvement in total skin disease, and patients who saw an initial response thanks to MRG-106 generally maintained those responses with continued therapy. Additionally, it has been generally well tolerated at doses from 75 mg to 900 mg.
“We are pleased with these interim results from our MRG-106 Phase 1 trial, which includes seven patients who maintained a durable response for at least four months,” said Dr. Paul Rubin, miRagen’s executive vice president of Research and Development. “We plan to initiate a controlled Phase 2 trial in the second half of 2018 to further evaluate the potential of MRG-106.”